These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 37262395)

  • 1. Frontline Management of Nodal Peripheral T-Cell Lymphomas.
    Ngu HS; Savage KJ
    Am Soc Clin Oncol Educ Book; 2023 May; 43():e390334. PubMed ID: 37262395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Past, present and future therapeutic approaches in nodal peripheral T-cell lymphomas.
    Ngu HS; Savage KJ
    Haematologica; 2023 Dec; 108(12):3211-3226. PubMed ID: 38037799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retrospective Analysis With Propensity Score Matching of Peripheral T-Cell Lymphoma Treated Frontline With Brentuximab Vedotin and Chemotherapy.
    Burke JM; Liu N; Yu KS; Fanale MA; Surinach A; Flores C; Lisano J; Phillips T
    Oncologist; 2023 Jun; 28(6):520-530. PubMed ID: 36971492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hematopoietic Cell Transplantation and Adoptive Cell Therapy in Peripheral T Cell Lymphoma.
    Rogers AM; Brammer JE
    Curr Hematol Malig Rep; 2020 Aug; 15(4):316-332. PubMed ID: 32529515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of brentuximab vedotin plus chemotherapy for previously untreated CD30-positive peripheral T-cell lymphoma in Canada.
    Zou D; Lee J; Kansal A; Ma W; Harris M; Lisano J; Fenton K; Yu KS
    J Med Econ; 2022; 25(1):324-333. PubMed ID: 35172685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 study.
    Herrera AF; Zain J; Savage KJ; Feldman T; Brammer JE; Chen L; Puverel S; Popplewell L; Budde LE; Mei M; Hosing C; Nair R; Leslie L; Daniels S; Peters L; Forman S; Rosen S; Kwak L; Iyer SP
    Lancet Haematol; 2024 Sep; 11(9):e671-e681. PubMed ID: 39067464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brentuximab vedotin in the treatment of CD30+ PTCL.
    Barta SK; Gong JZ; Porcu P
    Blood; 2019 Dec; 134(26):2339-2345. PubMed ID: 31697814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDA Approval Summary: Brentuximab Vedotin in First-Line Treatment of Peripheral T-Cell Lymphoma.
    Richardson NC; Kasamon YL; Chen H; de Claro RA; Ye J; Blumenthal GM; Farrell AT; Pazdur R
    Oncologist; 2019 May; 24(5):e180-e187. PubMed ID: 30914464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical and economic burden of peripheral T-cell lymphoma: a systematic literature review.
    Ashaye AO; Burnett H; Abogunrin S; Panchmatia H; Ovcinnikova O; Dalal M
    Future Oncol; 2022 Feb; 18(4):519-535. PubMed ID: 34851173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Short-Term Efficacy and Safety of Brentuximab Vedotin Plus Cyclophosphamide, Epirubicin and Prednisone in Untreated PTCL: A Real-World, Retrospective Study.
    Feng X; Guo W; Wang Y; Li J; Zhao Y; Qu L; Yan X; Li J; Guo Q; Young KH; Bai O
    Adv Ther; 2022 Jan; 39(1):532-543. PubMed ID: 34797505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2.
    Savage KJ; Horwitz SM; Advani R; Christensen JH; Domingo-Domenech E; Rossi G; Morschhauser F; Alpdogan O; Suh C; Tobinai K; Shustov A; Trneny M; Yuen S; Zinzani PL; Trümper L; Ilidge T; O'Connor OA; Pro B; Miao H; Bunn V; Fenton K; Fanale M; Puhlmann M; Iyer S
    Blood Adv; 2022 Oct; 6(19):5550-5555. PubMed ID: 35470385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy.
    Abramson JS; Feldman T; Kroll-Desrosiers AR; Muffly LS; Winer E; Flowers CR; Lansigan F; Nabhan C; Nastoupil LJ; Nath R; Goy A; Castillo JJ; Jagadeesh D; Woda B; Rosen ST; Smith SM; Evens AM
    Ann Oncol; 2014 Nov; 25(11):2211-2217. PubMed ID: 25193992
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas.
    Fanale MA; Horwitz SM; Forero-Torres A; Bartlett NL; Advani RH; Pro B; Chen RW; Davies A; Illidge T; Uttarwar M; Lee SY; Ren H; Kennedy DA; Shustov AR
    Blood; 2018 May; 131(19):2120-2124. PubMed ID: 29507077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study.
    Fanale MA; Horwitz SM; Forero-Torres A; Bartlett NL; Advani RH; Pro B; Chen RW; Davies A; Illidge T; Huebner D; Kennedy DA; Shustov AR
    J Clin Oncol; 2014 Oct; 32(28):3137-43. PubMed ID: 25135998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma.
    Shea L; Mehta-Shah N
    Curr Hematol Malig Rep; 2020 Feb; 15(1):9-19. PubMed ID: 32016790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma.
    Horwitz S; O'Connor OA; Pro B; Trümper L; Iyer S; Advani R; Bartlett NL; Christensen JH; Morschhauser F; Domingo-Domenech E; Rossi G; Kim WS; Feldman T; Menne T; Belada D; Illés Á; Tobinai K; Tsukasaki K; Yeh SP; Shustov A; Hüttmann A; Savage KJ; Yuen S; Zinzani PL; Miao H; Bunn V; Fenton K; Fanale M; Puhlmann M; Illidge T
    Ann Oncol; 2022 Mar; 33(3):288-298. PubMed ID: 34921960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Durable Response to Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, and Prednisone (BV-CHP) in a Patient with CD30-Positive PTCL Arising as a Post-Transplant Lymphoproliferative Disorder (PTLD).
    Hong J; Johnson WT; Kartan S; Gonsalves AS; Fenkel JM; Gong JZ; Porcu P
    Curr Oncol; 2021 Dec; 28(6):5067-5072. PubMed ID: 34940065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peripheral T-cell lymphoma: From biology to practice to the future.
    O'Connor OA; Ma H; Chan JYS; Kim SJ; Yoon SE; Kim WS
    Cancer Treat Rev; 2024 Sep; 129():102793. PubMed ID: 39002211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The aggressive peripheral T-cell lymphomas: 2013.
    Armitage JO
    Am J Hematol; 2013 Oct; 88(10):910-8. PubMed ID: 24078271
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnosis, management and follow up of peripheral T-cell lymphomas: a consensus practice statement from the Australasian Lymphoma Alliance.
    Hapgood G; Latimer M; Lee ST; Kuss B; Lade S; Tobin JWD; Purtill D; Campbell BA; Prince HM; Hawkes EA; Shortt J; Radeski D
    Intern Med J; 2022 Oct; 52(10):1806-1817. PubMed ID: 34668281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.